Abstract
Can serial FCH-PET/CT scans predict the response to treatments in castrate resistant prostate cancer?
Highlights
Prostate cancer is the most frequent tumor in males and both the availability of prostate specific antigen (PSA) testing and the extension of median life expectancy are responsible for a significant increase of incidence registered in the last decades.Endocrine therapies represent the first-choice for patients found with advanced disease at diagnosis or relapsing after local treatments, with an average time to progression (TTP) of 18-24 months to the so-called “Castrate-resistant” phase when diseases progresses notwithstanding low levels of circulating testosterone[1]
Inclusion criteria for this study were: (1) patients with histological diagnosis of prostate cancer, any Gleason, any type of local treatment; (2) metastatic castrateresistant prostate cancer (mCRPCa) disease with bone and/or visceral metastases showing a pathologic uptake on a baseline FCH-positron emission tomography (PET)/computed tomography (CT) scan which is confirmed by biopsy or conventional imaging (such as bone scan, magnetic resonance imaging (MRI), CT and radiography); (3) no fewer than two FCH-PET/CT scans separated by at least one month and by no more than 12 months whilst receiving therapy; (4) treatment with systemic anticancer agents for mCRPCa, first or subsequent line; 4) no therapy at the time of baseline FCH-PET/CT; 4) no granulocyte colonystimulating factor for at least two weeks before FCHPET/CT
The majority of patients were treated by radical prostatectomy and lymph node dissection (n=9; 42.9%), followed or not by adjuvant radiotherapy
Summary
Endocrine therapies (either luteinizing hormone-releasing hormone analogues, anti-androgens or combined) represent the first-choice for patients found with advanced disease at diagnosis or relapsing after local treatments, with an average time to progression (TTP) of 18-24 months to the so-called “Castrate-resistant” phase when diseases progresses notwithstanding low levels of circulating testosterone[1]. 10-20% of patients with localized prostate cancer developed metastatic castrateresistant prostate cancer (mCRPCa) within 5-years of follow-up after initial therapy, while the majority of patients with metastatic disease at diagnosis become castrate-resistant within a shorter interval time [2]. Docetaxel has long been the only treatment able to improve survival of mCRPCa and still represents the first cytotoxic option. Patients have currently at least three further options with the ability to impact on survival: namely cabazitaxel, abiterone acetate and enzalutamide. 223-radium has been a proven treatment for mCRPCa, with excellent palliative effects as well as increases in overall survival [5,6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
